Molteni Purchase Agreement (Details Textual) $ in Millions	1 Months Ended	3 Months Ended
Molteni Purchase Agreement (Details Textual) $ in Millions	Aug. 31, 2018 USD ($)	Mar. 31, 2019 USD ($)	Mar. 31, 2019 EUR (€)	Aug. 31, 2018 EUR (€)
Purchase Agreement [Line Items]
Proceeds from Sale of Productive Assets		$ 2.4	€ 2,000,000
Revenue Recognition Milestone Methods Description		earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory in percentages ranging from the low-teens to the mid-twenties.	earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory in percentages ranging from the low-teens to the mid-twenties.
Long-term Purchase Commitment, Milestones	In August 2018, we entered into an amendment (the “Amendment”) to the Molteni Purchase Agreement. Under the Amendment, Molteni made an immediate payment to us of €950,000 (approximately $1.1 million) and a convertible loan of €550,000 (approximately $0.6 million) (“Molteni Convertible Loan”) (see Note 6), both in exchange for the elimination of an aggregate of €2.0 million (approximately $2.3 million) of regulatory milestones provided for in the Molteni Purchase Agreement that are potentially payable in 2019, at the earliest.
Revenue Recognition Milestone Method Payment	$ 1.1	$ 1.4
Amount Received Under Amendment To Purchase Agreement	1.1			€ 950,000
Convertible Debt	$ 0.6			€ 550,000